In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19.
Cell Metab
; 32(2): 176-187.e4, 2020 08 04.
Article
in English
| MEDLINE | ID: covidwho-612919
ABSTRACT
Statins are lipid-lowering therapeutics with favorable anti-inflammatory profiles and have been proposed as an adjunct therapy for COVID-19. However, statins may increase the risk of SARS-CoV-2 viral entry by inducing ACE2 expression. Here, we performed a retrospective study on 13,981 patients with COVID-19 in Hubei Province, China, among which 1,219 received statins. Based on a mixed-effect Cox model after propensity score-matching, we found that the risk for 28-day all-cause mortality was 5.2% and 9.4% in the matched statin and non-statin groups, respectively, with an adjusted hazard ratio of 0.58. The statin use-associated lower risk of mortality was also observed in the Cox time-varying model and marginal structural model analysis. These results give support for the completion of ongoing prospective studies and randomized controlled trials involving statin treatment for COVID-19, which are needed to further validate the utility of this class of drugs to combat the mortality of this pandemic.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Angiotensin-Converting Enzyme Inhibitors
/
Coronavirus Infections
/
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/
Drug Repositioning
/
Antihypertensive Agents
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Cell Metab
Journal subject:
Metabolism
Year:
2020
Document Type:
Article
Affiliation country:
J.cmet.2020.06.015
Similar
MEDLINE
...
LILACS
LIS